SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in community engagement and social media momentum as supporters rally around the project's 'culture-first' branding and upcoming milestones. Investors are increasingly connecting the token to broader cannabis sector trends and shifting regulatory sentiment, positioning it as a grassroots-driven alternative within the decentralized ecosystem.

Praetorian Acquisition Corp. - Ordinary Shares - Class A

Investors are closely monitoring Praetorian Acquisition Corp. following its recent public debut as the market evaluates the potential for future merger and acquisition activity from the newly formed blank check company.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive pivot toward private credit and AI-driven infrastructure against lingering concerns regarding industry-wide redemption pressures and valuation risks in the real estate sector. The community is sharply divided, with some betting on a long-term turnaround fueled by record dry powder and strategic deployment, while others are closely monitoring potential liquidity constraints that could signal broader credit cycle risks.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is currently seeing significant momentum as investors digest its latest quarterly results, which showcased accelerating revenue growth and improved margins that suggest its AI-driven model is gaining traction. The stock remains a focal point for the retail community, who are actively debating its valuation versus its disruptive potential, while some traders continue to monitor for short-squeeze opportunities driven by high short interest and institutional interest.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is experiencing significant market volatility driven by speculation around potential strategic partnerships and its role in emerging crypto-finance infrastructure. Investors are actively debating the impact of recent dilution, the company'spivot toward stablecoin settlement, and the potential for a short squeeze as the community monitors upcoming investor events.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to the announcement that its commercial-grade GP2 vials are approved and actively being used in the FLAMINGO-01 Phase 3 clinical trial, signaling a major operational milestone and de-risking of the supply chain. The community is heavily focused on the elite Steering Committees unprecedented co-authorship of upcoming AACR conference abstracts, with long-term investors interpreting this as a strong vote of confidence in the trials progress toward interim results.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as investors react to the recent appointment of a new CFO and continued speculation regarding a potential hyperscaler tenant for its data center campus. Community discourse remains divided, with supporters highlighting upcoming catalysts and infrastructure scale, while skeptics point to the lack of official contract announcements and concerns over the company's delivery timeline.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley shares are surging following a strong third-quarter earnings report, where significant growth in investment banking fees and record-breaking wealth management results topped analyst expectations. The community is actively discussing the firm's robust trading performance and capitalizing on its strong market positioning as part of a broader rally in the financial sector.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is generating significant market interest as momentum traders track strengthening price structures and bullish call option activity ahead of upcoming earnings. The community is actively debating the stock's potential for a breakout, driven by ongoing M&A speculation, sector-wide energy demand, and analysts identifying the stock as an undervalued acquisition candidate.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense investor focus as the semiconductor material specialist captures attention for its strategic role in the AI-driven photonics and data center infrastructure supply chain. The community is actively debating the company's growth potential amid ongoing geopolitical tensions, with discussions polarized between those focused on the high-demand bottleneck for indium phosphide wafers and others skeptical of the valuation relative to past financial performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Esperion highlighted future growth plans, including expanding U.S. market penetration and advancing its oral triple-combination program.</li><li>The company said that its acquisition of Corstasis Therapeutics also advances its Vision 2040 strategy.</li><li>Esperion also added that it plans to expand geographically through continued collaboration with its global partners.</li></ul>Esperion Therapeutics Inc. (ESPR) shares fell more than 6% in Tuesday morning’s trade after the company reported a mixed fourth quarter.Esperion reported earnings per share (EPS) of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million, according to Fiscal.ai data.“2025 was a defining year for Esperion. We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin-intolerant or statin-resistant patients, and strengthened the durability of our business with important intellectual property and market access advances,” said Esperion CEO Sheldon Koenig.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ESPR">Esperion</a> trended in the ‘extremely bullish’ territory despite the mixed fourth-quarter (Q4) performance. Message volumes were at ‘extremely high’ levels at the time of writing.One bullish user stated that the ESPR stock appears way undervalued.<stembedurl>https://stocktwits.com/DP000/message/647094104</stembedurl>Another user stated that Esperion has massive catalysts coming up.<stembedurl>https://stocktwits.com/BRLondon/message/647092901</stembedurl><h2 class="st-heading-2">Esperion Highlights Upcoming Catalysts</h2>Esperion stated that it is investing in several clear catalysts for future growth. These include deeper penetration in the U.S. market supported by strong payer coverage, as well as progress on its oral triple-combination program designed to compete with products currently on the market or in development.The firm also added that it plans to expand geographically through continued collaboration with its global partners.“We are entering 2026 with confidence, discipline, and a long-term mindset focused on creating lasting value for patients, providers, and shareholders,” Koenig added.The company said that it aims to pursue new therapeutic opportunities and develop next-generation inhibitors targeting multiple life-threatening diseases.ACLY is a metabolic enzyme involved in breaking down nutrients and producing cholesterol and fatty acids, making it a potential target for treating a range of diseases.<h2 class="st-heading-2">Koenig Says Corstasis Deal Advances Vision 2040</h2>During a post-earnings call with analysts, Koenig said that the planned acquisition of Cortasis Therapeutics advances the company’s Vision 2040.“The acquisition of Corstasis is a catalyst for additional long-term value and a testament to our commitment to building a larger and sustainably profitable company. Our priority is to grow these two franchises to their multi-billion-dollar potential,” he said.Esperion announced earlier this month that it had entered into an agreement to acquire Corstasis for an upfront payment of $75 million. Corstasis shareholders will also be eligible to receive an additional $180 million upon the attainment of certain regulatory and commercial milestones, as well as royalties on sales of Enbumyst and follow-on products.<a href="https://stocktwits.com/symbol/ESPR">ESPR stock</a> is down 21% year-to-date, but up more than 84% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-hims-deal-turns-wall-street-bullish-hims-stock-upgrades/cZdos7IRI7d">Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts

Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million.

Equity

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CANF Stock Soar 25% Today?

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint

TBPH company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

<ul class="summary-bullets"><li>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.</li><li>Nektar stated that patients receiving monthly and quarterly dosing regimens resulted in sustained disease control for EASI-75, EASI-90, and other indicators.</li><li>The company also noted that it observed an increase in patients who achieved EASI-100 in the 24 micrograms per kilogram dosing regimens in the monthly and quarterly time periods.</li></ul>Nektar Therapeutics Inc. (NKTR) shares rose more than 42% in Tuesday’s opening trade after the company reported positive results from its long-term atopic dermatitis trial.Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/NKTR">Nektar Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels. The NKTR stock was among the top ten trending tickers on the platform.<h2 class="st-heading-2">Nektar’s Findings In The Trial</h2>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.Nektar stated that patients receiving monthly and quarterly dosing regimens achieved sustained disease control as measured by EASI-75, EASI-90, the validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and the Itch Numerical Rating Scale (NRS) response.The company also noted an increase in patients achieving EASI-100 on the 24 micrograms per kilogram dosing regimens during the monthly and quarterly periods.EASI refers to the Eczema Area and Severity Index. It quantifies the severity and extent of eczema symptoms across body regions. EASI-75 points to a greater than or equal to 75% improvement from baseline, while EASI-90 refers to a 90% or more improvement. Similarly, EASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">Retail Gives A Thumbs Up</h2>One bullish user observed that “patience does pay off,” while adding that they are not selling the stock.<stembedurl>https://stocktwits.com/aristocks/message/644554531</stembedurl>Another user stated that there is nothing to “even remotely” criticize Nektar for, following the announcement of the trial results.<stembedurl>https://stocktwits.com/clarksonhockey/message/644552638</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up 24% year-to-date and 204% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-fisv-stock-falling-today/cZbU3sOR4Yp">Why Is FISV Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

<ul class="summary-bullets"><li>Anaphylm is Aquestive’s sublingual epinephrine film for allergic reactions.</li><li>The Anaphylm application is supported by 11 clinical studies involving 411 subjects, the company said.</li><li>Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA date on January 31, it added.</li></ul>Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that currently prevent labeling discussions on Anaphylm.Anaphylm is Aquestive’s sublingual (under the tongue) epinephrine film for allergic reactions.However, the FDA also confirmed its review of the New Drug Application (NDA) remains ongoing, and no final decision has been made.Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA (Prescription Drug User Fee Act) date on January 31, noting that delays in receiving details could impact the approval timeline. A PDUFA date is the FDA's target date to make a decision on a drug application.The Anaphylm application is supported by 11 clinical studies involving 411 subjects, demonstrating pharmacokinetics comparable to epinephrine auto-injectors and a similar safety profile, Aquestive added.“As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time. Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns. The FDA stated that the notification does not reflect a final decision on the pending application and the FDA’s review remains ongoing,” said Dan Barber, President and Chief Executive Officer of Aquestive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the strong intraday decline, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/AQST">AQST</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_2de986106b.webp" alt="AQST.jpg">Over the past year, the stock has gained 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Plug Power said it was impacted by the speed and development of hydrogen economy.

Why Did AQST Stock Plunge 40% In Pre-Market Today?

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed 

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

XPH
SPDR Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XPH News

XPHSPDR Pharmaceuticals ETF